Sharmilan Thanendrarajan

High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

31 h-index 255 pubs 3,421 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Health disparities and outcomes Immune Response and Inflammation Immune Cell Function and Interaction Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers Meta-analysis and systematic reviews

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Sharmilan Thanendrarajan, M.D., is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences, with a focus on multiple myeloma research. His work investigates the evolutionary pathways of multiple myeloma, from its smoldering stage to relapsed and refractory states, utilizing molecular and single-cell level analyses of the immune microenvironment.

Dr. Thanendrarajan's research also addresses disparities in treatment access for multiple myeloma patients, specifically examining geographic and racial differences in access to clinical trials for advanced therapies like CAR-T cells and bispecific antibodies. He has published on the risk of infections associated with bispecific antibody therapies and the changing spectrum of infections with novel antibody treatments in relapsed refractory multiple myeloma.

With a substantial publication record (255 publications, 3,421 citations) and an h-index of 31, Dr. Thanendrarajan is recognized as a highly cited researcher. He collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Carolina Schinke, Samer Al Hadidi, and Frits van Rhee, and leads a research group focused on multiple myeloma.

Research Overview

Sharmilan Thanendrarajan, M.D., is an Assistant Professor of Medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.Dr. Thanendrarajan trained as a fellow in Hematology/Oncology at University Clinic of Bonn in Germany. He trained as a resident in Internal Medicine at University Clinic of Bonn and General Hospital of Hagen. Dr. Thanendrarajan earned his M.D. from the Medical College of Ruhr-University in Bochum, Germany. He is a member of the German Society of Internal Medicine, the German Cancer Society, the German Society for Hematology and Oncology, the European Society for Medical Oncology and the European Myeloma Network. Dr. Thanendrarajan is board certified in Germany in Internal Medicine and Hematology/Oncology. Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=thanendrarajan+sTo make an appointment with Dr. Thanendrarajan, please call 1-888-MYELOMA.

Metrics

h-index: 31
Publications: 255
Citations: 3,421

Selected Publications

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025) DOI
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024) DOI
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI
Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma (2023) DOI
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study (2023) DOI